Amicus Therapeutics Inc

+0.29 (+2.28%)
6:57:32 PM EDT: $13.50 +0.46 (+3.53%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)3.66B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$85.64 Million
Adjusted EPS-$0.11
See more estimates
10-Day MA$12.93
50-Day MA$12.18
200-Day MA$10.54
See more pivots

Amicus Therapeutics Inc Stock, NASDAQ:FOLD

3675 Market Street, Philadelphia, Pennsylvania 19104
United States of America
Phone: +1.215.921.7600
Number of Employees: 496


Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.